abstract |
The present invention is a new modified release pharmaceutical composition containing sofosbuvir and ribavirin, as well as at least one pharmaceutically acceptable excipient for use in the treatment of infections caused by the hepatitis C virus, chronic hepatitis C (CHC), hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation. |